AARD
AARD
Positions held
Your positionsAARD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
2026-10-02 · Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-24 · Aardvark Therapeutics' ARD-101 Path Forward May Be Challenging, RBC Says
2026-09-14 · Aardvark Therapeutics Insider Sold Shares Worth $394,957, According to a Recent SEC Filing
2026-08-17 · Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...
Price (daily)
Full chart · RSI · MACD · patterns